Last updated: February 13, 2026
Overview:
The drug with NDC 59651-0671 is X, a biologic indicated for Y. Its market landscape features a competitive environment with multiple biologics targeting similar indications. As of 2023, the drug's patent status, approval timeline, and market penetration influence current market dynamics and future price trajectories.
Market Landscape
Therapeutic Area & Competition
The drug targets Y, which includes a market of approximately Z patients worldwide. The main competitors are Pfizer’s Z, Novartis’s Z, and Eli Lilly’s Z. The biologics market for this indication is estimated at $A billion globally, with a compound annual growth rate (CAGR) of B% from 2020-2023.
Market Penetration & Adoption
Since approval in Year, the drug has captured about C% market share. Usage is concentrated in North America (D%), Europe (E%), and Asia (F%). Payer coverage limitations and high costs pose barriers, though partnerships with major insurers expedite adoption.
Regulatory & Patent Status
The patent for the drug expires in Year, with litigation and biosimilar development underway. Manufacturer efforts to extend exclusivity involve supplementary indications, formulations, or patent challenges.
Price History and Current Price Point
Historical Pricing Data:
- Launch Price (Year): $G per unit
- 2021: $H, with a % decrease/increase due to payer negotiations and market entry of biosimilars
- 2022: Stabilized at approximately $I per unit
- Current Price (2023): $J, reflecting market saturation and competitive pressures
Pricing Benchmarks:
Compared to its main competitors:
- Drug Z: $K per unit
- Biosimilar X: $L per unit
The brand maintains a premium over biosimilars by approximately M%.
Price Projection Factors
Patent and Regulatory Timeline
Patent expiry in Year opens the market for biosimilars, likely causing price erosion of 20-30% within 2 years post-expiry. The FDA approval of biosimilar candidates is expected by Year.
Market Penetration of Biosimilars
Biosimilar adoption in the US could reach X% within 3 years of patent expiry, with discounts of Y% on current prices.
Supply Chain & Manufacturing Costs
Production costs for biologics are increasing due to raw material prices, but economies of scale may limit steep price reductions pre-patent expiry.
Payer & Reimbursement Policies
Payer push for biosimilar uptake will influence pricing, coupled with value-based agreements that tie reimbursement levels to clinical outcomes.
Price Projections (2024-2028)
| Year |
Estimated Market Price |
Drivers & Assumptions |
| 2024 |
$J* |
Slight decrease due to early biosimilar entry, estimates of X% biosimilar market penetration |
| 2025 |
$K* |
Greater biosimilar competition, additional market share shifts |
| 2026 |
$L* |
Post-patent expiry, biosimilar dominance with price reductions of Y% |
| 2027 |
$M* |
Stabilization at a lower price point, reflecting biosimilar uptake |
| 2028 |
$N* |
Market equilibrium expected, with a potential rebound if supply constraints exist |
(Prices are in USD per unit; actual figures depend on final approvals and market conditions.)
Key Takeaways
- The drug's market is influenced heavily by patent expiration in Year, with biosimilar competitors expected to gain substantial market share, reducing prices by up to 30% over two years.
- Current pricing maintains a premium over biosimilar alternatives, but a decline is forecasted post-patent expiry.
- Adoption rates depend on payer policies and formulary decisions; regions with aligned reimbursement policies poised for quicker biosimilar uptake may see more significant price erosion.
- The competitive landscape and regulatory environment suggest a gradual decline in retail prices, stabilizing at lower levels by Year.
FAQs
1. When does patent expiry for NDC 59651-0671 occur?
The patent is scheduled to expire in Year, allowing biosimilars to enter the market subsequent to this date.
2. How much can I expect the price to decline after patent expiry?
Prices could decrease by 20-30% within two years of biosimilar market entry.
3. Which regions are most susceptible to price reductions?
The US and Europe will experience faster biosimilar adoption, leading to more immediate price competition.
4. What factors could delay biosimilar entry or price decreases?
Patent litigation, regulatory delays, or manufacturer strategies to extend exclusivity may postpone biosimilar availability.
5. How does payer negotiating power influence future pricing?
Payers seeking cost containment will push for biosimilar uptake, exerting downward pressure on prices through formulary prioritization and rebate negotiations.
Sources:
[1] FDA Biosimilar Approval Data (2023)
[2] MarketResearch.com, Biologics Market Overview (2023)
[3] IQVIA Biologic Pricing (2023)
[4] Patent & Litigation Data (USPTO, 2023)
